UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses

Pharmacotherapy, 2016-03, Vol.36 (3), p.317-334

2016

Volltextzugriff (PDF)

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors

OncoTargets and therapy, 2017-01, Vol.10, p.2097-2106

2017

Volltextzugriff (PDF)

Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors

Clinical therapeutics, 2007-07, Vol.29 (7), p.1338-1353

2007

Volltextzugriff (PDF)

Risk Stratification for Bleeding Complications in Patients With Venous Thromboembolism: Application of the HAS‐BLED Bleeding Score During the First 6 Months of Anticoagulant Treatment

Journal of the American Heart Association, 2018-03, Vol.7 (6), p.n/a

2018

Volltextzugriff (PDF)

Vena Cava Filter Retrieval Rates and Factors Associated With Retrieval in a Large US Cohort

Journal of the American Heart Association, 2017-09, Vol.6 (9), p.n/a

2017

Volltextzugriff (PDF)

Doxorubicin and Paclitaxel-Loaded Lipid-Based Nanoparticles Overcome Multidrug Resistance by Inhibiting P-Glycoprotein and Depleting ATP

Cancer research (Chicago, Ill.), 2009-05, Vol.69 (9), p.3918-3926

2009

Volltextzugriff (PDF)

Sticky Issues: What APs Need to Know About Anticoagulants and Patients With Cancer

Journal of the advanced practitioner in oncology, 2021-04, Vol.12 (3), p.262-265

2021

Volltextzugriff (PDF)

Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study

Thrombosis research, 2017-10, Vol.158, p.49-58

2017

Volltextzugriff (PDF)

Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization

European journal of pharmaceutics and biopharmaceutics, 2009-05, Vol.72 (1), p.9-17

2009

Volltextzugriff (PDF)

Pharmacokinetics of Intravenous Levofloxacin Administered at 750 Milligrams in Obese Adults

Antimicrobial Agents and Chemotherapy, 2011-07, Vol.55 (7), p.3240-3243

2011

Volltextzugriff (PDF)

Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies

Healthcare (Basel), 2016-02, Vol.4 (1), p.16

2016

Volltextzugriff (PDF)

Optimizing postgraduate year 3 training

American journal of health-system pharmacy, 2014-11, Vol.71 (22), p.1924-1925

2014

Volltextzugriff (PDF)

Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma

Healthcare (Basel), 2016-12, Vol.4 (4), p.93

2016

Volltextzugriff (PDF)

The Reversal of Inhibitors in Congenital Hemophilia

Pharmacotherapy, 2013-02, Vol.33 (2), p.157-164

2013

Volltextzugriff (PDF)

Histological and genetic markers for non-small-cell lung cancer: Customizing treatment based on individual tumor biology

American journal of health-system pharmacy, 2010-01, Vol.67 (1 Supplement 1), p.S3-S9

2010

Volltextzugriff (PDF)

Concurrent Everolimus With Hepatic Transarterial Bland Embolotherapy in Patients With Metastatic Well-Differentiated Neuroendocrine Tumors

Oncology (Williston Park, N.Y.), 2020-11, Vol.34 (11), p.471

2020

Volltextzugriff (PDF)

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

Investigational new drugs, 2005-01, Vol.23 (1), p.39-49

2005

Volltextzugriff (PDF)

Use of histological and genetic markers in optimizing therapy for patients with non-small-cell lung cancer: introduction

American journal of health-system pharmacy, 2010-01, Vol.67 (1), p.S1

2010

Volltextzugriff (PDF)

Inactivation of the Ketoreductase gilU Gene of the Gilvocarcin Biosynthetic Gene Cluster Yields New Analogues with Partly Improved Biological Activity

Chembiochem : a European journal of chemical biology, 2009-01, Vol.10 (2), p.278-286

2009

Volltextzugriff (PDF)

Competing Risks Analysis of Cancer-associated Recurrent Thrombosis, Major Bleeds, and Death in a Geriatric Cohort

Journal of health economics and outcomes research (Online), 2015-12, Vol.4 (1), p.1-18

2015

Volltextzugriff (PDF)

Cytotoxic Activities of New Jadomycin Derivatives

Journal of antibiotics, 2005-06, Vol.58 (6), p.405-408

2005

Volltextzugriff (PDF)

Evolving role of antineoplastic agents in colorectal cancer

American journal of health-system pharmacy, 2006-05, Vol.63 (9 Supplement 2), p.S4-S11

Adams, Val R

2006

Volltextzugriff (PDF)

Multiple sclerosis outcomes after cancer immunotherapy

Clinical & translational oncology, 2019-10, Vol.21 (10), p.1336-1342

2019

Volltextzugriff (PDF)

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors

The oncologist (Dayton, Ohio), 2023-06, Vol.28 (6), p.479-485

2023

Volltextzugriff (PDF)

Anticancer Activity of Novel Unnatural Synthetic Isoprenoids

Anticancer research, 2010-07, Vol.30 (7), p.2505-2512

2010

Volltextzugriff (PDF)

1 – 25 von 218

Suche als RSS-Feed

Aktive Filter

KollektionSAGE Publications

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(200)

Publikationsform

Sprache

Englisch
(216)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors

Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors

Risk Stratification for Bleeding Complications in Patients With Venous Thromboembolism: Application of the HAS‐BLED Bleeding Score During the First 6 Months of Anticoagulant Treatment

Vena Cava Filter Retrieval Rates and Factors Associated With Retrieval in a Large US Cohort

Doxorubicin and Paclitaxel-Loaded Lipid-Based Nanoparticles Overcome Multidrug Resistance by Inhibiting P-Glycoprotein and Depleting ATP

Sticky Issues: What APs Need to Know About Anticoagulants and Patients With Cancer

Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study

Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization

Pharmacokinetics of Intravenous Levofloxacin Administered at 750 Milligrams in Obese Adults

Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies

Optimizing postgraduate year 3 training

Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma

The Reversal of Inhibitors in Congenital Hemophilia

Histological and genetic markers for non-small-cell lung cancer: Customizing treatment based on individual tumor biology

Concurrent Everolimus With Hepatic Transarterial Bland Embolotherapy in Patients With Metastatic Well-Differentiated Neuroendocrine Tumors

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

Use of histological and genetic markers in optimizing therapy for patients with non-small-cell lung cancer: introduction

Inactivation of the Ketoreductase gilU Gene of the Gilvocarcin Biosynthetic Gene Cluster Yields New Analogues with Partly Improved Biological Activity

Competing Risks Analysis of Cancer-associated Recurrent Thrombosis, Major Bleeds, and Death in a Geriatric Cohort

Cytotoxic Activities of New Jadomycin Derivatives

Evolving role of antineoplastic agents in colorectal cancer

Multiple sclerosis outcomes after cancer immunotherapy

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors

Anticancer Activity of Novel Unnatural Synthetic Isoprenoids

Aktive Filter

Suchergebnisse filtern